Birat Journal Of Health Sciences
ISSN (Online): 2542-2804 • Quarterly • Vol. 8, No. 2 (2022)

Clinical Characteristics and Early Management Outcomes of Neonatal Respiratory Distress Syndrome

Michael Kidd[1]
[1]Department of Family and Community Medicine, University of Toronto, Toronto, Canada
Email: michael.kidd@utoronto.ca

ARTICLE HISTORY

RECEIVED	REVISED	ACCEPTED	PUBLISHED ONLINE
[12 May 2022]	*[15 July 2022]*	*[20 August 2022]*	*[31 August 2022]*

Abstract

Neonatal respiratory distress syndrome (NRDS) is a major respiratory disorder affecting premature newborns and is associated with pulmonary surfactant deficiency, reduced lung compliance, impaired gas exchange, and increased respiratory effort. The condition remains an important cause of neonatal respiratory failure, particularly among infants born at extremely low gestational ages. Early recognition and appropriate management are essential for improving survival, reducing respiratory complications, and supporting long-term pulmonary development. This narrative review evaluates the clinical characteristics, diagnostic considerations, risk factors, early therapeutic interventions, and management outcomes associated with neonatal respiratory distress syndrome. Evidence from randomized controlled trials, systematic reviews, and international consensus guidelines indicates that antenatal corticosteroids, early noninvasive respiratory support, selective surfactant replacement, and lung-protective ventilation can improve selected neonatal outcomes. Nevertheless, the effectiveness of individual interventions varies according to gestational age, disease severity, treatment timing, and available neonatal intensive care resources. Early continuous positive airway pressure can reduce exposure to invasive ventilation, while less invasive surfactant administration offers potential benefits for selected preterm infants. Important complications include pneumothorax, bronchopulmonary dysplasia, respiratory failure, and mortality. The review emphasizes the importance of timely diagnosis, individualized respiratory support, careful oxygen monitoring, and multidisciplinary neonatal care. Evidence-based early management can improve respiratory stabilization while reducing treatment-related lung injury in premature newborns.

Keywords: Neonatal Respiratory Distress Syndrome, Prematurity, Pulmonary Surfactant Deficiency, Neonatal Respiratory Failure, Continuous Positive Airway Pressure, Surfactant Replacement Therapy, Neonatal Intensive Care, Bronchopulmonary Dysplasia, Mechanical Ventilation, Neonatal Clinical Outcomes

COPYRIGHT & LICENSE

Copyright © 2026 The Author(s). All rights reserved by the author(s), who retain copyright ownership of their original work. The author(s) grant the **Birat Journal of Health Sciences (BJHS)** a non-exclusive right of first publication.

Open Access License: This article is published under the [Creative Commons Attribution 4.0 International (CC BY 4.0) License](https://creativecommons.org/licenses/by/4.0/), permitting unrestricted use, distribution, reproduction, and adaptation in any medium, including commercial use, provided that appropriate credit is given to the original author(s), the source and the license, and any modifications are clearly indicated.

1. Introduction

Neonatal respiratory distress syndrome is an important respiratory condition associated primarily with premature birth and insufficient pulmonary surfactant production. Pulmonary surfactant is a complex substance produced by alveolar type II epithelial cells that reduces surface tension within the lungs and helps maintain alveolar stability during breathing. In premature infants, inadequate

surfactant availability contributes to alveolar collapse, reduced lung compliance, and increased respiratory effort. The risk of respiratory distress syndrome increases as gestational age decreases because pulmonary maturation is closely related to fetal development. Extremely premature infants are particularly vulnerable because their lungs may have insufficient surfactant reserves and structurally immature gas-exchange surfaces. The severity of respiratory distress is influenced by gestational age, antenatal medical care, associated illnesses, and the effectiveness of initial respiratory support. Clinical manifestations commonly begin shortly after birth and include rapid breathing, expiratory grunting, nasal flaring, chest retractions, and increased oxygen requirements. Severe cases may progress to respiratory acidosis, recurrent apnea, and respiratory failure. Early differentiation from other causes of neonatal respiratory distress is important because pneumonia, transient tachypnea, meconium aspiration, congenital heart disease, and persistent pulmonary hypertension may produce overlapping clinical findings. Advances in neonatal intensive care have substantially changed the management of respiratory distress syndrome. Antenatal corticosteroids can accelerate fetal lung maturation, while early continuous positive airway pressure and selective surfactant replacement help maintain adequate pulmonary function. Modern treatment increasingly emphasizes noninvasive respiratory support and avoidance of unnecessary mechanical ventilation to reduce the risk of treatment-related lung injury. Despite these improvements, NRDS remains associated with significant neonatal morbidity, particularly among extremely premature infants and newborns in healthcare settings with limited respiratory support resources. Early management outcomes depend on the timely application of appropriate interventions, careful monitoring, and coordinated neonatal care. This article examines six important dimensions of neonatal respiratory distress syndrome: clinical presentation and risk factors, diagnostic assessment, early respiratory stabilization, surfactant administration, short-term clinical outcomes, and future evidence-based management strategies.

Clinical Presentation, Gestational Risk Factors, and Pathophysiological Characteristics of Neonatal Respiratory Distress Syndrome

Neonatal respiratory distress syndrome develops primarily because immature lungs contain insufficient functional surfactant to maintain adequate alveolar expansion. Surfactant deficiency increases alveolar surface tension, promoting collapse during expiration and increasing the pressure required to reopen the air spaces. The resulting reduction in lung compliance leads to increased respiratory effort and impaired oxygen exchange. As alveolar instability progresses, newborns may develop hypoxemia, carbon dioxide retention, and respiratory acidosis. These physiological abnormalities contribute to the characteristic clinical manifestations observed during the first hours of life (Reuter et al., 2014). Gestational age represents one of the strongest determinants of respiratory distress syndrome risk. Infants born at extremely early gestational ages have immature alveolar structures, limited surfactant production, and reduced capacity to maintain stable functional residual lung volume. Although pulmonary maturation progresses throughout pregnancy, the extent of lung development varies among individual infants. The most recent European consensus recommendations emphasize that extremely preterm infants remain particularly vulnerable to respiratory failure and frequently require intensive respiratory support. Appropriate assessment should therefore consider gestational age together with the newborn's actual respiratory condition rather than relying on gestation alone (Sweet et al., 2026). Common clinical manifestations include tachypnea, expiratory grunting, nasal flaring, intercostal and subcostal retractions, and increasing supplemental oxygen requirements. Grunting represents an attempt to maintain airway pressure during expiration, while chest retractions reflect increased respiratory effort associated with reduced lung compliance. Some infants demonstrate relatively mild symptoms initially but deteriorate as pulmonary atelectasis becomes more extensive. Severe respiratory distress may be accompanied by cyanosis, poor perfusion, apnea, or reduced respiratory effort. These findings require prompt neonatal assessment and appropriate respiratory stabilization (Reuter et al., 2014). Maternal and perinatal factors also influence the likelihood of NRDS. Premature delivery, inadequate exposure to antenatal corticosteroids, and certain maternal medical conditions may increase the risk of respiratory problems after birth. Antenatal corticosteroid treatment is an established intervention for women at risk of

premature delivery because it promotes fetal lung maturation and reduces important neonatal complications. A Cochrane systematic review demonstrated that antenatal corticosteroids reduce respiratory distress syndrome and neonatal mortality in appropriate preterm populations. These benefits highlight the importance of communication between obstetric and neonatal teams before anticipated premature birth (McGoldrick et al., 2020). The clinical severity of NRDS depends on the interaction between pulmonary immaturity and the physiological transition from intrauterine to extrauterine life. At birth, the lungs must establish adequate aeration while clearing fetal lung fluid and adapting to pulmonary circulation. Surfactant deficiency interferes with this process by promoting alveolar collapse and reducing functional lung capacity. The infant may compensate through rapid breathing and increased respiratory effort, but these mechanisms can become insufficient when disease severity increases. Early respiratory support aims to stabilize alveolar expansion while minimizing additional injury to immature lung tissue (Sweet et al., 2026). Several factors can complicate clinical presentation. Neonatal infection, hemodynamic instability, hypothermia, and associated congenital conditions may contribute to respiratory distress independently of surfactant deficiency. Some newborns may have more than one underlying problem, making careful evaluation necessary. Clinical signs should therefore be interpreted alongside perinatal history, gestational age, physiological measurements, and the response to initial treatment. Failure to recognize alternative or additional diagnoses may result in inappropriate respiratory management (Reuter et al., 2014). The progression of NRDS can be rapid, particularly among extremely premature infants who have limited respiratory reserves. Increasing oxygen requirements, persistent retractions, recurrent apnea, and deteriorating blood gas measurements may indicate worsening respiratory function. However, the decision to escalate treatment should be individualized because unnecessary invasive ventilation can also cause pulmonary injury. Early recognition depends on repeated assessment of respiratory effort, oxygenation, ventilation, and general clinical stability (Sweet et al., 2026). Understanding clinical characteristics and risk factors is essential for anticipating treatment requirements and identifying infants who may benefit from early surfactant administration. A structured approach combining gestational assessment, maternal history, and continuous clinical surveillance can improve recognition while supporting timely selection of appropriate respiratory interventions.

Diagnostic Evaluation, Respiratory Severity Assessment, and Early Clinical Monitoring

The diagnosis of neonatal respiratory distress syndrome is based on the combination of clinical findings, gestational history, respiratory support requirements, and appropriate investigations. There is no single clinical sign that definitively establishes the diagnosis in every newborn. Prematurity, early onset of respiratory distress, progressive oxygen requirements, and evidence of reduced lung aeration strongly support NRDS. Nevertheless, other neonatal respiratory conditions may produce similar symptoms, requiring systematic differential diagnosis (Reuter et al., 2014). Clinical examination remains the foundation of early evaluation. Healthcare professionals should assess respiratory rate, chest movement, grunting, nasal flaring, retractions, air entry, and the infant's overall condition. Increasing work of breathing may indicate worsening respiratory mechanics, while reduced respiratory effort may suggest fatigue or impending respiratory failure. Continuous observation is important because respiratory severity can change rapidly during the first hours following birth. The need for increasing inspired oxygen concentration or escalating airway pressure should prompt reassessment of treatment effectiveness (Sweet et al., 2026). Pulse oximetry is an essential monitoring method because it provides continuous information about arterial oxygen saturation. Appropriate oxygen management is particularly important in premature newborns because both inadequate oxygenation and excessive oxygen exposure can contribute to complications. Oxygen requirements should be adjusted according to neonatal resuscitation and intensive care protocols, considering the infant's gestational age and clinical condition. Research examining oxygen concentrations during resuscitation of extremely premature infants demonstrates that determining optimal oxygen exposure requires balancing competing physiological risks (Oei et al., 2017). Blood gas analysis may provide additional information about respiratory function, particularly in infants with moderate or severe disease. Elevated carbon dioxide, reduced oxygenation, and abnormal blood pH can indicate

inadequate ventilation or gas exchange. These measurements are useful when evaluating persistent respiratory distress, treatment failure, or the need for invasive ventilation. However, results should be interpreted in relation to clinical examination and respiratory support settings. Excessive reliance on isolated laboratory measurements may result in unnecessary intervention when the infant is otherwise stable (Sweet et al., 2026). Chest radiography has historically been used to identify features associated with surfactant deficiency, including reduced lung volume, diffuse fine granular opacities, and air bronchograms. However, these findings are not always present early in the disease course, particularly when noninvasive respiratory support and surfactant treatment are initiated promptly. The most recent consensus guidelines emphasize that classical radiographic findings may represent relatively late manifestations of untreated or progressive disease. Imaging should therefore support clinical assessment rather than delay necessary stabilization (Sweet et al., 2026). DOI Differential diagnosis is particularly important because transient tachypnea of the newborn, neonatal pneumonia, meconium aspiration syndrome, persistent pulmonary hypertension, and congenital heart conditions may resemble NRDS. Transient tachypnea is more commonly associated with delayed clearance of fetal lung fluid, while pneumonia may involve maternal infection risk factors and additional systemic findings. Congenital cardiac conditions may produce hypoxemia that does not respond as expected to routine respiratory support. A structured evaluation can help identify these possibilities and determine whether additional investigations are required (Reuter et al., 2014). The response to initial treatment provides important diagnostic and prognostic information. Improvement following continuous positive airway pressure or surfactant replacement may support the presence of surfactant-related lung disease, but treatment response should not be considered a definitive diagnostic test. Infants with additional conditions may demonstrate partial improvement or continued respiratory instability. Serial assessment of oxygen requirements, respiratory effort, blood gases, and cardiovascular status is therefore necessary throughout early management (Sweet et al., 2026). Early diagnostic evaluation should aim to guide safe clinical decisions without delaying necessary respiratory treatment. In settings with limited diagnostic equipment, systematic clinical observation and pulse oximetry remain especially important. Healthcare teams should establish clear escalation procedures and ensure that infants with persistent or severe respiratory distress can access appropriate neonatal intensive care. Timely diagnosis and monitoring provide the foundation for effective early management and complication prevention (Reuter et al., 2014).

Early Respiratory Stabilization, Noninvasive Ventilation, and Oxygen Management

Early respiratory stabilization is a central component of neonatal respiratory distress syndrome management because respiratory support must maintain adequate gas exchange while minimizing injury to immature lungs. Modern neonatal care increasingly emphasizes noninvasive respiratory support for spontaneously breathing preterm infants who do not require immediate intubation. Continuous positive airway pressure helps maintain alveolar expansion, improve functional residual capacity, and reduce the work of breathing. This approach can support pulmonary transition after birth while potentially avoiding some complications associated with invasive mechanical ventilation (Sweet et al., 2026). Nasal continuous positive airway pressure has been investigated extensively in premature newborns. The COIN randomized trial enrolled 610 infants born between 25 and 28 weeks of gestation and compared early nasal CPAP with intubation and ventilation. Death or bronchopulmonary dysplasia at 36 weeks occurred in 33.9% of infants assigned to CPAP and 38.9% of those assigned to intubation. The difference was not statistically significant, but the study contributed important evidence regarding the feasibility of initiating respiratory support without routine immediate intubation. Clinicians must also consider complications such as pneumothorax when using noninvasive pressure support (Morley et al., 2008). New England Journal of Medicine The SUPPORT trial further evaluated early CPAP compared with early surfactant treatment among extremely premature infants. In this large randomized study, the two approaches did not demonstrate a statistically significant difference in the primary composite outcome of death or bronchopulmonary dysplasia. However, infants initially assigned to CPAP were less likely to require intubation and received fewer days of mechanical ventilation. These findings supported a treatment strategy in which

suitable infants begin with noninvasive respiratory support while clinicians continue to evaluate the need for surfactant and escalation of treatment (SUPPORT Study Group, 2010). A systematic review and meta-analysis comparing noninvasive with invasive respiratory support at birth found that initiating treatment with noninvasive support was associated with improved outcomes in preterm infants. The analysis supported early CPAP as an appropriate approach for many newborns at risk of respiratory distress syndrome, particularly when facilities have the capacity to identify treatment failure promptly. Nevertheless, noninvasive support is not suitable for every infant, and those with severe respiratory failure or inadequate spontaneous breathing may require intubation (Schmölzer et al., 2013). Oxygen management is another essential aspect of early stabilization. Premature lungs are vulnerable to oxidative injury, but inadequate oxygen delivery may also compromise vital organs. Supplemental oxygen should therefore be carefully titrated using reliable monitoring and established neonatal protocols. Evidence examining higher versus lower oxygen concentrations during resuscitation of infants born before 28 weeks of gestation has highlighted uncertainty concerning optimal initial oxygen strategies. These findings reinforce the importance of avoiding both prolonged hypoxemia and unnecessary exposure to excessive oxygen concentrations (Oei et al., 2017). Alternative forms of noninvasive respiratory support include nasal intermittent positive pressure ventilation and heated humidified high-flow nasal cannula therapy. These methods differ in the airway pressure they provide, the availability of respiratory assistance, and the characteristics of their interfaces. Nasal intermittent positive pressure ventilation may provide additional support for selected infants experiencing respiratory instability. A systematic review found that early nasal intermittent positive pressure ventilation may reduce respiratory failure and the need for intubation compared with CPAP, although the certainty of evidence and magnitude of benefit vary across outcomes (Lemyre et al., 2023a). High-flow nasal therapy has also been investigated as primary respiratory support for premature newborns. In the HIPSTER randomized trial, 564 preterm infants with early respiratory distress were assigned to either high-flow therapy or CPAP. High-flow therapy resulted in a higher rate of treatment failure than CPAP, leading to early termination of the trial. These findings demonstrated that high-flow therapy should not automatically be considered equivalent to CPAP as initial respiratory support, particularly when the ability to provide rescue treatment is limited (Roberts et al., 2016). The effectiveness of early respiratory stabilization depends on continuous monitoring and timely treatment escalation. Increasing oxygen requirements, recurrent apnea, worsening respiratory acidosis, or sustained respiratory distress may indicate that the current support method is insufficient. Clinical teams should evaluate whether surfactant therapy, additional noninvasive support, or invasive ventilation is required. Appropriate decisions depend on gestational age, disease severity, local protocols, and available expertise (Sweet et al., 2026).

Clinical Characteristics and Early Management Approaches in Neonatal Respiratory Distress Syndrome

Clinical characteristic or condition	Clinical significance	Early management approach	Expected clinical objective
Premature birth	Increased risk of surfactant deficiency	Antenatal risk assessment and neonatal preparedness	Reduce severe respiratory complications
Tachypnea and chest retractions	Increased respiratory effort	Clinical assessment and appropriate respiratory support	Improve respiratory stability
Expiratory grunting	Attempt to maintain alveolar pressure	Early CPAP when indicated	Support alveolar expansion
Increasing oxygen requirement	Progressive impairment of gas exchange	Oxygen titration and evaluation for surfactant	Improve oxygenation while limiting toxicity
Recurrent apnea	Inadequate respiratory	Respiratory support and	Reduce apnea-

	drive or significant instability	appropriate caffeine therapy	related deterioration
Surfactant deficiency	Alveolar collapse and reduced compliance	Selective surfactant replacement	Improve lung compliance and gas exchange
Failure of noninvasive support	Persistent respiratory insufficiency	Escalation to invasive ventilation when indicated	Maintain adequate ventilation
Risk of bronchopulmonary dysplasia	Potential long-term respiratory morbidity	Lung-protective ventilation and reduced invasive exposure	Limit pulmonary injury
Hemodynamic instability	Compromised tissue perfusion	Cardiovascular evaluation and individualized support	Preserve systemic circulation

Surfactant Replacement Therapy, Treatment Timing, and Early Respiratory Outcomes

Surfactant replacement therapy is a major advancement in the treatment of neonatal respiratory distress syndrome because it directly addresses the physiological consequences of pulmonary surfactant deficiency. Exogenous surfactant reduces alveolar surface tension, improves lung compliance, promotes alveolar stability, and facilitates oxygen exchange. The effectiveness of treatment depends on the severity of surfactant deficiency, the timing of administration, the delivery technique, and the infant's overall clinical condition. Modern approaches emphasize selective early surfactant treatment for infants demonstrating clinically significant RDS rather than routine invasive treatment for every premature newborn (Sweet et al., 2026). Early investigations established the benefits of combining surfactant replacement with noninvasive respiratory support. A randomized multicenter study involving 68 infants with moderate-to-severe respiratory distress syndrome compared surfactant administration followed by nasal CPAP with CPAP alone. Subsequent mechanical ventilation was required by 43% of the surfactant-treated infants compared with 85% of controls. The findings demonstrated that surfactant therapy could improve oxygenation and reduce the need for invasive ventilation among selected newborns. However, subsequent developments in neonatal care have changed the techniques and criteria used for surfactant administration (Verder et al., 1994). Traditional surfactant administration often required endotracheal intubation followed by mechanical ventilation. The intubate-surfactant-extubate approach was developed to reduce prolonged ventilation exposure by allowing infants to return to noninvasive respiratory support after treatment. Although this strategy can be effective, intubation and positive-pressure ventilation may expose immature lungs to mechanical stress. Less invasive surfactant administration techniques were subsequently developed to deliver surfactant while preserving spontaneous breathing and CPAP support (Kanmaz et al., 2013). Thin-catheter surfactant administration is an important example of this approach. During the procedure, surfactant is introduced into the trachea through a narrow catheter while the infant continues receiving noninvasive respiratory support. A randomized controlled trial involving preterm infants younger than 32 weeks compared thin-catheter administration with the intubate-surfactant-extubate method. The investigators reported a reduced requirement for mechanical ventilation within the first 72 hours in the thin-catheter group. These findings suggested that avoiding routine intubation during surfactant delivery may improve selected early respiratory outcomes (Kanmaz et al., 2013). The potential benefits of less invasive surfactant administration have also been examined among extremely premature infants. The NINSAPP randomized clinical trial included 211 infants and compared nonintubated surfactant administration with conventional treatment. Survival without bronchopulmonary dysplasia at 36 weeks was not significantly different between groups. Nevertheless, infants receiving less invasive surfactant had lower rates of selected complications, including pneumothorax and severe intraventricular hemorrhage, and experienced less exposure to

mechanical ventilation. These findings indicate that early treatment success should be evaluated through multiple clinical outcomes rather than a single composite endpoint (Kribs et al., 2015). The OPTIMIST-A trial provides additional evidence concerning the effectiveness and limitations of minimally invasive surfactant therapy. This multicenter randomized trial included 485 premature infants born at 25–28 weeks of gestation who required supplemental oxygen while receiving CPAP. Death or bronchopulmonary dysplasia occurred in 43.6% of infants assigned to minimally invasive surfactant therapy compared with 49.6% of controls, a difference that was not statistically significant. Although the trial did not establish superiority for the primary outcome, its findings contributed important information about early surfactant administration and the need for further evaluation of longer-term benefits (Dargaville et al., 2021). Treatment timing is an important consideration because delaying surfactant administration until severe respiratory deterioration occurs may increase the need for invasive ventilation. Conversely, providing surfactant to infants who are stabilizing successfully with noninvasive support may expose them to unnecessary procedures. Clinical decisions should therefore consider oxygen requirements, gestational age, work of breathing, and the trajectory of respiratory illness. The European consensus guidelines recommend early rescue surfactant for eligible infants and support thin-catheter administration when appropriate expertise and monitoring are available (Sweet et al., 2026). The administration of surfactant also requires careful procedural planning. Healthcare professionals must assess the newborn's respiratory stability, establish appropriate monitoring, and prepare for complications such as transient oxygen desaturation, bradycardia, or treatment failure. The benefits of avoiding intubation should be balanced against the need for adequate stabilization during the procedure. Training and clinical experience influence the feasibility of less invasive approaches, particularly in extremely premature infants with limited physiological reserves (Kanmaz et al., 2013). Early outcomes following surfactant treatment should include changes in oxygen requirements, respiratory effort, blood gas parameters, and the need for escalation to mechanical ventilation. Longer-term outcomes, including bronchopulmonary dysplasia and survival, remain important but are influenced by many factors beyond the initial surfactant procedure. The available evidence supports selective and timely administration while emphasizing that treatment technique should be individualized according to infant characteristics and neonatal unit capabilities (Dargaville et al., 2021).

Short-Term Clinical Outcomes, Respiratory Complications, and Neonatal Intensive Care Management

The evaluation of early management outcomes in neonatal respiratory distress syndrome requires consideration of respiratory stabilization, treatment failure, complications, survival, and the duration of intensive care. Improvements in oxygenation and respiratory effort are important immediate indicators, but they do not fully represent the effectiveness of neonatal treatment. Premature infants may remain vulnerable to respiratory and systemic complications even after the initial signs of NRDS improve. Consequently, comprehensive outcome assessment should include both short-term physiological responses and clinically significant neonatal morbidity (Sweet et al., 2026). The need for invasive mechanical ventilation is a major outcome because prolonged exposure may contribute to respiratory complications in immature lungs. Mechanical ventilation can be lifesaving when noninvasive support is insufficient, but excessive airway pressures and lung volume changes may cause tissue injury. Modern neonatal management therefore emphasizes avoiding unnecessary intubation and limiting ventilation duration when invasive support is required. A systematic review and meta-analysis found that initiating respiratory support noninvasively was associated with favorable outcomes compared with routine early intubation in selected preterm populations (Schmölzer et al., 2013). Pneumothorax represents an important early respiratory complication. It occurs when air escapes from the pulmonary air spaces into the pleural cavity and may cause sudden respiratory deterioration. Premature infants receiving positive-pressure support can develop air-leak complications when fragile lung tissues are exposed to excessive pressure or uneven inflation. Clinical signs may include abrupt oxygen desaturation, increased respiratory distress, reduced breath sounds, and cardiovascular instability. Prompt recognition and treatment are important because clinically

significant pneumothorax may compromise ventilation and circulation (Reuter et al., 2014). Clinical trials have demonstrated that respiratory support strategies may influence pneumothorax risk. In the COIN trial, early CPAP reduced some measures of exposure to invasive respiratory treatment but was associated with a higher rate of pneumothorax than immediate intubation. Conversely, the NINSAPP trial reported fewer pneumothoraces among infants receiving less invasive surfactant therapy compared with conventional treatment. These findings demonstrate that respiratory support methods have different benefits and risks, and no single approach should be assumed to eliminate all pulmonary complications (Morley et al., 2008; Kribs et al., 2015). Bronchopulmonary dysplasia is a major longer-term respiratory complication associated with extreme prematurity and prolonged oxygen or ventilatory support. Its development involves complex interactions among pulmonary immaturity, inflammation, oxygen exposure, and treatment-related injury. The disorder is commonly assessed according to respiratory support or oxygen requirements at a defined postmenstrual age, although diagnostic criteria differ across research settings. Preventive strategies include appropriate antenatal management, early noninvasive support, timely surfactant treatment, careful oxygen regulation, and limiting unnecessary mechanical ventilation (Sweet et al., 2026). The Caffeine for Apnea of Prematurity trial provides evidence concerning an important supportive treatment in premature infants. The randomized trial included 2,006 infants with birth weights between 500 and 1,250 grams. Among surviving infants assessed at 36 weeks' postmenstrual age, bronchopulmonary dysplasia occurred in 36% of those assigned to caffeine compared with 47% of those assigned to placebo. Caffeine also facilitated earlier discontinuation of positive airway pressure. These findings support the role of caffeine in selected premature infants with apnea and respiratory support requirements, although caffeine is not a direct replacement for surfactant in treating NRDS (Schmidt et al., 2006). Postextubation respiratory support is another important component of early neonatal management. Infants recovering from invasive ventilation may require CPAP or nasal intermittent positive pressure ventilation to maintain adequate respiratory stability. A Cochrane systematic review comparing these approaches found that nasal intermittent positive pressure ventilation reduced the risk of respiratory failure and reintubation after extubation compared with nasal CPAP. However, evidence concerning some long-term outcomes remained uncertain, and treatment selection should consider gestational age, respiratory condition, and the capabilities of the neonatal unit (Lemyre et al., 2023b). Hemodynamic stability is closely related to respiratory outcomes because inadequate oxygenation and impaired circulation can affect multiple organ systems. Premature infants with severe respiratory distress may experience blood pressure abnormalities, altered tissue perfusion, and difficulties maintaining adequate temperature and metabolic balance. Appropriate management requires regular assessment of cardiovascular status, urine output, temperature, blood glucose, and other relevant indicators. Respiratory treatment should therefore be integrated with comprehensive neonatal intensive care rather than provided as an isolated intervention (Sweet et al., 2026). Nutrition and fluid management are additional considerations during early recovery. Premature infants have high nutritional requirements but may initially be unable to tolerate full enteral feeding. Respiratory instability and severe illness can complicate feeding decisions, requiring careful assessment of hydration, electrolyte balance, and nutritional support. Early appropriate nutrition contributes to overall neonatal recovery and growth, although feeding plans must be individualized according to gestational age and clinical stability. The latest European guidelines emphasize coordinated supportive care alongside respiratory treatment (Sweet et al., 2026). Infection prevention and appropriate antimicrobial management also influence neonatal outcomes. Respiratory distress syndrome may coexist with neonatal pneumonia or early-onset infection, and clinical findings can overlap. Infants with relevant maternal risk factors or signs suggesting infection may require diagnostic evaluation and empiric treatment according to local protocols. Nevertheless, unnecessary antibiotic exposure should be avoided when infection is not supported by clinical or microbiological evidence. Accurate assessment and timely reassessment are important for balancing infection treatment with antimicrobial stewardship (Reuter et al., 2014). The duration of hospitalization and the need for ongoing respiratory support are important indicators of overall recovery. However, length of


stay is influenced by gestational age, feeding maturity, temperature regulation, and other neonatal conditions, making it difficult to attribute hospitalization duration solely to NRDS treatment. Future evaluations should report respiratory outcomes separately from broader neonatal discharge outcomes to provide a more accurate understanding of intervention effectiveness (Sweet et al., 2026). Ultimately, successful early management should be assessed through survival, respiratory stabilization, avoidance of unnecessary invasive ventilation, reduction of complications, and appropriate developmental care. Neonatal teams should use standardized outcome measures while recognizing that extremely premature infants may experience complex medical courses despite appropriate initial treatment (Schmölzer et al., 2013).

Future Directions and Evidence-Based Strategies for Improving Neonatal Respiratory Distress Syndrome Outcomes

The future management of neonatal respiratory distress syndrome will depend on continued improvements in respiratory support, surfactant delivery, perinatal prevention, and neonatal intensive care organization. Advances in treatment have already shifted clinical practice toward strategies that preserve spontaneous breathing and reduce exposure to invasive ventilation. Nevertheless, major challenges remain, particularly among extremely premature infants who have limited pulmonary reserves and high risks of bronchopulmonary dysplasia. Future research should prioritize interventions that improve survival while minimizing short- and long-term complications (Sweet et al., 2026). Perinatal prevention remains a fundamental strategy because optimizing care before premature delivery can reduce the severity of neonatal respiratory illness. Antenatal corticosteroids promote fetal lung maturation and improve important neonatal outcomes when administered appropriately to women at risk of preterm birth. A Cochrane review identified reductions in respiratory distress syndrome, neonatal mortality, and several other serious complications following antenatal corticosteroid treatment. Future implementation efforts should focus on ensuring timely access for eligible pregnancies while avoiding inappropriate administration when preterm birth is unlikely (McGoldrick et al., 2020). Regionalization of neonatal care may further improve outcomes by facilitating delivery at centers equipped to manage extremely premature infants. Hospitals with specialized neonatal intensive care teams can provide appropriate respiratory support, surfactant administration, temperature control, and management of complex complications. However, transportation and referral systems must be organized carefully because delays in receiving appropriate care may affect early stabilization. The latest European consensus guidelines emphasize coordinated antenatal planning and transfer to suitable perinatal centers when appropriate (Sweet et al., 2026). Less invasive surfactant administration is expected to remain an important area of clinical development. Thin-catheter techniques allow selected spontaneously breathing premature infants to receive surfactant without routine prolonged intubation. Although clinical trials have demonstrated benefits involving reduced mechanical ventilation and selected complications, results concerning death and bronchopulmonary dysplasia have been less consistent. Future investigations should clarify which infants benefit most from minimally invasive treatment and whether improvements in short-term respiratory outcomes translate into sustained developmental advantages (Kribs et al., 2015). The timing of surfactant administration also requires continued evaluation. Early treatment may prevent deterioration among infants with clinically significant surfactant deficiency, but unnecessary intervention may increase procedural exposure. Identifying appropriate treatment thresholds could improve the balance between early support and avoidance of overtreatment. Research should consider gestational age, oxygen requirements, work of breathing, and clinical progression when developing individualized surfactant strategies. Studies should also distinguish procedure success from longer-term respiratory outcomes (Dargaville et al., 2021). Noninvasive ventilation technologies may offer additional opportunities for reducing invasive respiratory support. Nasal intermittent positive pressure ventilation and other noninvasive methods can provide greater respiratory assistance than conventional CPAP for selected infants. Evidence from systematic reviews suggests that early nasal intermittent positive pressure ventilation may reduce respiratory failure and intubation requirements compared with CPAP. However, differences in devices, synchronization,

patient selection, and treatment protocols complicate direct comparisons. Future randomized trials should use standardized interventions and clearly defined respiratory outcomes (Lemyre et al., 2023a). The role of heated humidified high-flow nasal therapy should also be investigated within specific clinical contexts. Although this approach offers advantages related to comfort and potentially reduced nasal trauma, evidence indicates that it is less effective than CPAP as primary respiratory support in some premature populations. The HIPSTER trial demonstrated a significantly higher treatment failure rate with high-flow therapy. Future evaluations should identify whether particular infants or stages of respiratory recovery are more suitable for this modality while ensuring that effective rescue support remains readily available (Roberts et al., 2016). Oxygen monitoring and individualized saturation management continue to require careful attention. Premature infants are vulnerable to both inadequate oxygen delivery and oxygen-related tissue injury. Improved monitoring technologies may help clinicians maintain appropriate oxygenation while avoiding excessive fluctuations. However, decisions regarding oxygen targets must be based on validated neonatal evidence and should account for gestational age and overall clinical condition. Research examining initial oxygen concentrations during delivery room resuscitation demonstrates the importance of balancing potential benefits against physiological risks (Oei et al., 2017). Long-term respiratory health should be incorporated into neonatal outcome assessment. Although immediate stabilization is essential, premature infants may experience ongoing respiratory vulnerability after discharge. Bronchopulmonary dysplasia and other complications can influence respiratory function, growth, and healthcare utilization during infancy and childhood. Future studies should therefore extend follow-up beyond neonatal hospitalization and examine respiratory morbidity alongside neurodevelopmental outcomes. Comprehensive evaluation can help determine whether early treatment strategies provide sustained benefits (Schmidt et al., 2006). Neurodevelopmental outcomes are particularly important because extremely premature infants may experience complications that extend beyond pulmonary disease. The long-term follow-up of the Caffeine for Apnea of Prematurity trial demonstrated that caffeine treatment was associated with improved survival without major neurodevelopmental disability at 18–21 months' corrected age. These findings illustrate the importance of evaluating neonatal respiratory interventions across multiple developmental domains rather than focusing exclusively on early oxygen requirements or ventilation duration (Schmidt et al., 2007). Future research should also examine the relationship between neonatal respiratory management and healthcare resource availability. In low-resource settings, hospitals may experience shortages of CPAP equipment, surfactant preparations, reliable oxygen delivery systems, and appropriately trained neonatal personnel. Such limitations can affect timely treatment and increase the risk of preventable complications. Implementation strategies should prioritize essential respiratory equipment, professional training, infection prevention, and reliable referral systems. Adaptation to local resources should preserve core principles of safe and evidence-based neonatal care (Sweet et al., 2026). Professional education remains fundamental to successful treatment. Neonatologists, pediatricians, nurses, respiratory therapists, and obstetric professionals must understand the clinical characteristics of NRDS and the indications for available interventions. Simulation-based training can support recognition of respiratory deterioration, appropriate CPAP use, surfactant preparation, and management of complications. Regular review of treatment protocols can help ensure that healthcare teams incorporate emerging evidence while maintaining consistent clinical practice (Reuter et al., 2014). Future studies should use standardized outcome definitions to improve comparisons across neonatal intensive care units. Relevant outcomes include the frequency of respiratory distress syndrome, surfactant administration, treatment failure, mechanical ventilation exposure, pneumothorax, bronchopulmonary dysplasia, mortality, and long-term respiratory function. Researchers should report gestational age and birth weight categories carefully because differences in patient maturity can substantially influence outcomes. Standardization may improve evidence synthesis and support more reliable evaluation of neonatal respiratory interventions (Schmölzer et al., 2013). Clinical governance and continuous quality improvement should also be incorporated into neonatal respiratory care. Hospitals can monitor treatment timing, CPAP failure, surfactant use,

oxygen exposure, and respiratory complications to identify opportunities for improvement. Multidisciplinary review of complex cases may support safer care and improved adherence to evidence-based protocols. These initiatives should emphasize patient outcomes and responsible intervention rather than simply increasing the use of advanced technologies (Sweet et al., 2026). Ultimately, future progress will depend on combining preventive maternal care, timely neonatal stabilization, individualized respiratory support, and long-term follow-up. The objective should be to provide effective treatment while protecting immature pulmonary and neurological systems from avoidable injury. Continued research and coordinated healthcare development can improve the quality and accessibility of neonatal respiratory care across different clinical environments (Dargaville et al., 2021).



Summary

Neonatal respiratory distress syndrome remains a significant respiratory condition among premature newborns because of pulmonary surfactant deficiency, reduced lung compliance, and impaired gas exchange. Clinical manifestations commonly include tachypnea, expiratory grunting, nasal flaring, chest retractions, and increasing oxygen requirements. The severity of disease is closely related to gestational maturity, associated medical conditions, and the effectiveness of early respiratory stabilization. Evidence from randomized controlled trials and systematic reviews supports antenatal corticosteroids, early noninvasive respiratory support, and selective surfactant replacement as important components of evidence-based management. Continuous positive airway pressure can reduce exposure to invasive ventilation in suitable infants, while less invasive surfactant administration offers benefits for selected premature newborns. However, not all interventions consistently reduce the combined outcome of death or bronchopulmonary dysplasia. Important complications include respiratory failure, pneumothorax, bronchopulmonary dysplasia, and associated neonatal morbidity. Early management should therefore emphasize careful oxygen titration, repeated clinical assessment, appropriate escalation of respiratory support, and comprehensive intensive care. Future improvements require standardized treatment pathways, improved access to neonatal respiratory equipment, continued professional education, and research examining both immediate and long-term outcomes. Coordinated obstetric and neonatal care can strengthen prevention and early intervention. An evidence-based approach integrating clinical recognition, individualized respiratory treatment, and multidisciplinary support is essential for

improving neonatal respiratory outcomes while minimizing complications associated with premature lung development.

References:

Dargaville, P. A., Kamlin, C. O. F., Orsini, F., et al. (2021). Effect of minimally invasive surfactant therapy vs sham treatment on death or bronchopulmonary dysplasia in preterm infants with respiratory distress syndrome: The OPTIMIST-A randomized clinical trial. JAMA, 326(24), 2478–2487. https://doi.org/10.1001/jama.2021.21892

Kanmaz, H. G., Erdeve, O., Canpolat, F. E., Mutlu, B., & Dilmen, U. (2013). Surfactant administration via thin catheter during spontaneous breathing: Randomized controlled trial. Pediatrics, 131(2), e502–e509. https://doi.org/10.1542/peds.2012-0603

Kribs, A., Roll, C., Göpel, W., et al. (2015). Nonintubated surfactant application vs conventional therapy in extremely preterm infants: A randomized clinical trial. JAMA Pediatrics, 169(8), 723–730. https://doi.org/10.1001/jamapediatrics.2015.0504

Lemyre, B., Deguise, M.-O., Benson, P., Kirpalani, H., Ekhaguere, O. A., & Davis, P. G. (2023a). Early nasal intermittent positive pressure ventilation (NIPPV) versus early nasal continuous positive airway pressure (NCPAP) for preterm infants. Cochrane Database of Systematic Reviews, 2023(7), CD005384. https://doi.org/10.1002/14651858.CD005384.pub3

Lemyre, B., Deguise, M.-O., Benson, P., Kirpalani, H., De Paoli, A. G., & Davis, P. G. (2023b). Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for preterm neonates after extubation. Cochrane Database of Systematic Reviews, 2023(7), CD003212. https://doi.org/10.1002/14651858.CD003212.pub4

McGoldrick, E., Stewart, F., Parker, R., & Dalziel, S. R. (2020). Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews, 2020(12), CD004454. https://doi.org/10.1002/14651858.CD004454.pub4

Morley, C. J., Davis, P. G., Doyle, L. W., Brion, L. P., Hascoet, J.-M., & Carlin, J. B. (2008). Nasal CPAP or intubation at birth for very preterm infants. The New England Journal of Medicine, 358(7), 700–708. https://doi.org/10.1056/NEJMoa072788

Oei, J. L., Vento, M., Rabi, Y., Wright, I., Finer, N., Rich, W., Kapadia, V., Aune, D., Rook, D., Tarnow-Mordi, W., & Saugstad, O. D. (2017). Higher or lower oxygen for delivery room resuscitation of preterm infants below 28 completed weeks gestation: A meta-analysis. Archives of Disease in Childhood - Fetal and Neonatal Edition, 102(1), F24–F30. https://doi.org/10.1136/archdischild-2016-310435

Reuter, S., Moser, C., & Baack, M. (2014). Respiratory distress in the newborn. Pediatrics in Review, 35(10), 417–428. https://doi.org/10.1542/pir.35-10-417

Roberts, C. T., Owen, L. S., Manley, B. J., Frøisland, D. H., Donath, S. M., Dalziel, K. M., Pritchard, M. A., Cartwright, D. W., Collins, C. L., Malhotra, A., & Davis, P. G. (2016). Nasal high-flow therapy for primary respiratory support in preterm infants. The New England Journal of Medicine, 375(12), 1142–1151. https://doi.org/10.1056/NEJMoa1603694

Schmidt, B., Roberts, R. S., Davis, P., Doyle, L. W., Barrington, K. J., Ohlsson, A., Solimano, A., & Tin, W. (2006). Caffeine therapy for apnea of prematurity. The New England Journal of Medicine, 354(20), 2112–2121. https://doi.org/10.1056/NEJMoa054065

Schmölzer, G. M., Kumar, M., Pichler, G., Aziz, K., O'Reilly, M., & Cheung, P.-Y. (2013). Non-invasive versus invasive respiratory support in preterm infants at birth: Systematic review and meta-analysis. BMJ, 347, f5980. https://doi.org/10.1136/bmj.f5980

SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network. (2010). Early CPAP versus surfactant in extremely preterm infants. The New England Journal of Medicine, 362(21), 1970–1979. https://doi.org/10.1056/NEJMoa0911783

Sweet, D. G., Carnielli, V. P., Greisen, G., Hallman, M., Klebermass-Schrehof, K., Lavizzari, A., Ozek, E., Te Pas, A., Roehr, C. C., Saugstad, O. D., Simeoni, U., Vento, M., Visser, G. H. A., & Speer, C. P. (2026). European consensus guidelines on the management of respiratory distress syndrome: 2025. Neonatology, 123(4), 514–539. https://doi.org/10.1159/000551062

Verder, H., Robertson, B., Greisen, G., Ebbesen, F., Albertsen, P., Lundstrøm, K., & Jacobsen, T. (1994). Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. The New England Journal of Medicine, 331(16), 1051–1055. https://doi.org/10.1056/NEJM199410203311603

Condò, V., Cipriani, S., Colnaghi, M., Bellù, R., Zanini, R., Bulfoni, C., Parazzini, F., & Mosca, F. (2017). Neonatal respiratory distress syndrome: Are risk factors the same in preterm and term infants? The Journal of Maternal-Fetal & Neonatal Medicine, 30(11), 1267–1272. https://doi.org/10.1080/14767058.2016.1210597

Shin, J., Choi, C. W., & Lee, B. K. (2024). Risk factors for refractory respiratory distress syndrome among very-low-birth-weight infants. BMC Pediatrics, 24, Article 677. https://doi.org/10.1186/s12887-024-05138-7

Yenuberi, H., Ross, B., Tirkey, R. S., Benjamin, S. J., Rathore, S., Karuppusami, R., Lal, A., Thomas, N., & Mathew, J. E. (2024). Late-preterm antenatal steroids for reduction of neonatal respiratory complications: A randomized controlled trial. Obstetrics & Gynecology, 143(4), 468–474. https://doi.org/10.1097/AOG.0000000000005520

Soll, R. F., & Lucey, J. F. (1991). Surfactant replacement therapy. Pediatrics in Review, 12(9), 261–267. https://doi.org/10.1542/pir.12-9-261

Pang, H., Zhang, B., Shi, J., Zang, J., & Qiu, L. (2019). Diagnostic value of lung ultrasound in evaluating the severity of neonatal respiratory distress syndrome. European Journal of Radiology, 116, 186–191. https://doi.org/10.1016/j.ejrad.2019.05.004

Ismail, R., El Raggal, N. M., Hegazy, L. A., Sakr, H. M., Eldafrawy, O. A., & Farid, Y. A. (2023). Lung ultrasound role in diagnosis of neonatal respiratory disorders: A prospective cross-sectional study. Children, 10(1), Article 173. https://doi.org/10.3390/children10010173

Sefic Pasic, I., Riera Soler, L., Vazquez Mendez, E., & Castillo Salinas, F. (2023). Comparison between lung ultrasonography and chest X-ray in the evaluation of neonatal respiratory distress syndrome. Journal of Ultrasound, 26(2), 435–448. https://doi.org/10.1007/s40477-022-00728-6

De Martino, L., Yousef, N., Ben-Ammar, R., Raimondi, F., Shankar-Aguilera, S., & De Luca, D. (2018). Lung ultrasound score predicts surfactant need in extremely preterm neonates. Pediatrics, 142(3), e20180463. https://doi.org/10.1542/peds.2018-0463

SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network. (2010). Early CPAP versus surfactant in extremely preterm infants. The New England Journal of Medicine, 362(21), 1970–1979. https://doi.org/10.1056/NEJMoa0911783

Roberts, C. T., Owen, L. S., Manley, B. J., Frøisland, D. H., Donath, S. M., Dalziel, K. M., Pritchard, M. A., Cartwright, D. W., Collins, C. L., Malhotra, A., & Davis, P. G. (2016). Nasal high-flow therapy for primary respiratory support in preterm infants. The New England Journal of Medicine, 375(12), 1142–1151. https://doi.org/10.1056/NEJMoa1603694

Manley, B. J., Owen, L. S., Doyle, L. W., Andersen, C. C., Cartwright, D. W., Pritchard, M. A., Donath, S. M., & Davis, P. G. (2013). High-flow nasal cannulae in very preterm infants after extubation. The New England Journal of Medicine, 369(15), 1425–1433. https://doi.org/10.1056/NEJMoa1300071

Hodgson, K. A., Wilkinson, D., De Paoli, A. G., & Manley, B. J. (2023). Nasal high flow therapy for primary respiratory support in preterm infants. Cochrane Database of Systematic Reviews, 2023(5), CD006405. https://doi.org/10.1002/14651858.CD006405.pub4

Göpel, W., Kribs, A., Ziegler, A., Laux, R., Hoehn, T., Wieg, C., Siegel, J., Avenarius, S., von der Wense, A., Vochem, M., Groneck, P., Weller, U., Möller, J., Härtel, C., Haller, S., Roth, B., & Herting, E. (2011). Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): An open-label, randomised, controlled trial. The Lancet, 378(9803), 1627–1634. https://doi.org/10.1016/S0140-6736(11)60986-0

Dargaville, P. A., Kamlin, C. O. F., Orsini, F., Wang, X., De Paoli, A. G., Kanmaz Kutman, H. G., Cetinkaya, M., Kornhauser-Cerar, L., Derrick, M., Özkan, H., Hulzebos, C. V., Schmölzer, G. M., Aiyappan, A.,

Lemyre, B., Kuo, S., Rajadurai, V. S., O'Shea, J., Biniwale, M., Ramanathan, R., ... Davis, P. G. (2021). Effect of minimally invasive surfactant therapy vs sham treatment on death or bronchopulmonary dysplasia in preterm infants with respiratory distress syndrome: The OPTIMIST-A randomized clinical trial. JAMA, 326(24), 2478–2487. https://doi.org/10.1001/jama.2021.21892

Silveira, R. C., Panceri, C., Munõz, N. P., Carvalho, M. B., Fraga, A. C., & Procianoy, R. S. (2024). Less invasive surfactant administration versus intubation-surfactant-extubation in the treatment of neonatal respiratory distress syndrome: A systematic review and meta-analyses. Jornal de Pediatria, 100(1), 8–24. https://doi.org/10.1016/j.jped.2023.05.008

Ramaswamy, V. V., Bandyopadhyay, T., Abiramalatha, T., Pullattayil S, A. K., Szczapa, T., Wright, C. J., & Roehr, C. C. (2023). Clinical decision thresholds for surfactant administration in preterm infants: A systematic review and network meta-analysis. eClinicalMedicine, 62, 102097. https://doi.org/10.1016/j.eclinm.2023.102097

Schmidt, B., Roberts, R. S., Davis, P., Doyle, L. W., Barrington, K. J., Ohlsson, A., Solimano, A., & Tin, W. (2006). Caffeine therapy for apnea of prematurity. The New England Journal of Medicine, 354(20), 2112–2121. https://doi.org/10.1056/NEJMoa054065

Bassler, D., et al. (2015). Early inhaled budesonide for the prevention of bronchopulmonary dysplasia. The New England Journal of Medicine, 373(16), 1497–1506. https://doi.org/10.1056/NEJMoa1501917

Pérez-Tarazona, S., Marset, G., Part, M., López, C., & Pérez-Lara, L. (2022). Definitions of bronchopulmonary dysplasia: Which one should we use? The Journal of Pediatrics, 251, 67–73.e2. https://doi.org/10.1016/j.jpeds.2022.05.037

Katz, T. A., Bancalari, E., Gordijn, S. J., Higgins, R. D., Isayama, T., Jensen, E. A., Offringa, M., Pillow, J. J., Shah, P. S., Soll, R. F., Stoecklin, B., Mugie, S. M., van Kaam, A. H., & Onland, W. (2026). Toward a harmonized bronchopulmonary dysplasia definition: An international Delphi process. Pediatrics, 157(5), e2025074308. https://doi.org/10.1542/peds.2025-074308

Sweet, D. G., Carnielli, V. P., Greisen, G., Hallman, M., Klebermass-Schrehof, K., Lavizzari, A., Ozek, E., Te Pas, A., Roehr, C. C., Saugstad, O. D., Simeoni, U., Vento, M., Visser, G. H. A., & Speer, C. P. (2026). European consensus guidelines on the management of respiratory distress syndrome: 2025. Neonatology, 123(4), 514–539. https://doi.org/10.1159/000551062

Sweet, D. G., Carnielli, V. P., Greisen, G., Hallman, M., Klebermass-Schrehof, K., Ozek, E., Te Pas, A., Plavka, R., Roehr, C. C., Saugstad, O. D., Simeoni, U., Speer, C. P., Vento, M., Visser, G. H. A., & Halliday, H. L. (2023). European consensus guidelines on the management of respiratory distress syndrome: 2022 update. Neonatology, 120(1), 3–23. https://doi.org/10.1159/000528914

Liu, J., Inchingolo, R., Suryawanshi, P., Guo, B.-B., Kurepa, D., González Cortés, R., Yan, W., Chi, J.-H., Acosta, C. M., Jagła, M., Sharma, D., Sorantin, E., Hsieh, K.-S., Graziani, G., Malta, B., Woods, P., Meng, Q., You, C.-M., Kruczek, P., ... Feletti, F. (2025). Guidelines for the use of lung ultrasound to optimise the management of neonatal respiratory distress: International expert consensus. BMC Medicine, 23, Article 114. https://doi.org/10.1186/s12916-025-03879-5

Sweet, D. G., Carnielli, V., Greisen, G., Hallman, M., Ozek, E., Te Pas, A., Plavka, R., Roehr, C. C., Saugstad, O. D., Simeoni, U., Speer, C. P., Vento, M., Visser, G. H. A., & Halliday, H. L. (2019). European consensus guidelines on the management of respiratory distress syndrome: 2019 update. Neonatology, 115(4), 432–450. https://doi.org/10.1159/000499361